Benefitfocus Aktie
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Benefitfocus Aktie Analyse
| 19.10.18 | Benefitfocus Outperform | Wedbush Morgan Securities Inc. | |
| 28.04.17 | Benefitfocus Buy | Chardan Capital Markets | |
| 06.01.17 | Benefitfocus Buy | Chardan Capital Markets | |
| 10.03.16 | Benefitfocus Buy | Canaccord Adams | |
| 11.03.15 | Benefitfocus Buy | Canaccord Adams |
Werbung
Werbung